Patent intelligence · US
US 11623002
ALK polypeptides and methods of use thereof
ALK polypeptides and methods of use thereof
Patent details — US 11623002
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 11, 2023
- Expiration
- Apr 6, 2043
- Applicant
- Elicio Therapeutics, Inc.
- Claims
- 5
- CPC classes
- A61K, A61K2039/55555, A61K2039/6018, A61K2039/6031
Quick answer
US 11623002 (ALK polypeptides and methods of use thereof) is held by Elicio Therapeutics, Inc.. Status: granted. Granted Apr 11, 2023. Expires Apr 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Elicio Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K2039/55555, A61K2039/6018, A61K2039/6031, A61K2039/627, A61K31/4545
More from Elicio Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11623002?
US 11623002 (ALK polypeptides and methods of use thereof) is held by Elicio Therapeutics, Inc.. Status: granted. Granted Apr 11, 2023. Expires Apr 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11623002?
Elicio Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11623002 expire?
Our index shows an expiration date of Apr 6, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.